Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary
Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.
How this was made
The 30-second read
Why it matters
Traders can update models using the specific raised FY organic revenue and adjusted EPS ranges, the increased 2026 share repurchase authorization, and the stated margin headwind from U.S. SG&A and commercial buildout.
Market read
The call provides concrete FY guidance upgrades and a larger buyback plan, while also acknowledging margin pressure and China weakness, creating a balanced but tradable setup for estimate revisions.
What to watch
China is described as a major headwind for knees, and the article flags S.E.T. segment pressure points in trauma and restorative therapies, which could challenge the durability of the growth engine.
Background
This is a Q2 2026 earnings call summary for Zimmer Biomet, covering commercial execution, technology adoption, M&A integration approach, and full-year outlook.
Ticker impact
Zimmer Biomet raised full-year organic revenue guidance to 2.25% to 3.25% and adjusted EPS to $8.47 to $8.59, plus a $1B 2026 buyback plan.
Likely positive bias for the next few sessions as traders reprice FY EPS and buyback support, tempered by the stated >50 bps margin decline.
The article provides specific, time-relevant numerical guidance changes and a larger repurchase authorization, which typically drive estimate revisions. Offsetting signals include intentional margin compression and a China knee decline.
Market effects
Orthopedics med-tech investors may read the raised guidance and technology adoption (ROSA, AI navigation) as supportive for procedure-linked demand and capital spending.
China weakness (down 20% in the period) highlights ongoing regional demand divergence, potentially affecting sentiment toward international knee growth.
If the guidance assumes stable pricing erosion and a healthy procedural market, it can influence broader expectations for orthopedic procedure volumes and payer mix resilience.
Counterpoint
The raised guidance may be offset by the company’s own expectation of more than 50 bps full-year margin decline from front-loaded U.S. investments, which could cap upside if costs run hot.
Key entities
- public_companyZimmer Biomet Holdings, Inc.
Raised full-year organic constant currency revenue guidance to 2.25% to 3.25% and adjusted EPS to $8.47 to $8.59, with $1B planned 2026 share repurchases.
- product_platformROSA robotic suite
Technology and Data sales surged 53% in the U.S., tied to surgeon enthusiasm for the ROSA robotic suite.
- acquisition_integrationParagon 28 integration
Management says Paragon 28 integration is a template for future M&A, maintaining mid-teens growth with negligible key-personnel turnover.
